To what extent are those impacted by #lungcancer in Europe involved in shared decision making?

People & caregivers impacted are invited to complete this short, anonymous survey from Lung Cancer Europe.
Takes only 10-15 mins. 👉de.surveymonkey.com/r/LuCESurvey20…

#lcsm #Patient #Advocacy

Amazing #patientadvocates speaking with IASLC about #lungcancer #cancersupport #advocacy . Listen in👇
Yvonne Diaz AnnabelleGurwitch #lcsm

Seeing more and more 5+ year survival for Lung Cancer is the very definition of hope - Yvonne Diaz
D. Ross Camidge
oncodaily.com/blog/65412.html

#Cancer #LCSM #Cancer Survival #OncoDaily #Oncology

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression

'With combined osimertinib and palbociclib treatment as second line of treatment, he has an ongoing partial response at 10 months of follow-up.'

nature.com/articles/s4169…

Today we pay tribute to the life & legacy of Ilissa, another young mom gone way too soon from lung cancer. Visibility of YLC honors the past, present, & future survivors of change. #neverforget #lcsm #medtwitter #cancerjourney #bohky #anyonewithlungs ylci.org/tribute/ilissa…

The ongoing development of Nuvalent’s zidesamtinib (NVL-520) is an important step forward for our ROS-1 #lungcancer & #cancer community. Here Dr Stephen V Liu, MD highlights the great promise & limited low grade toxicities.

onclive.com/view/dr-liu-on…

#lcsm ROS1ders UK The ROS1ders, Inc.

Healthcare marketing seems to be realising that you can’t trawl your way through blogs and the internet to understand the “patient experience.”

Seems the notion of talking to people with the lived experience is still novel - via The Drum

thedrum.com/opinion/2024/0…

Our ALKtALK replay on Empowering Wellness w/ Dr Narjust Florez, MD, FASCO is now available.

We discuss the big issues across our community. In this snippet, Dr Florez shares the industry discussion on finding effective doses over maximum tolerated ones.

📺youtu.be/fxtLVrfAUrQ?si… #LCSM

We had an an amazing ALKtALK with the one and only Dr Narjust Florez, MD, FASCO. We spanned all the vital topics - from weight gain, relationships, sexual health & more.

We'll be sharing our replay shortly. Here's a behind the scenes shot with our co-hosts Summer, Yvonne & Dana. #LCSM

Lung cancer has many faces! Each person's journey is unique #Cancersurvivorship ALK Positive ALK+ International Yvonne Diaz Narjust Florez, MD, FASCO

Looking forward to helping to host our ALK Positive ALKtALK tonight w/ the amazing Dr Narjust Florez, MD, FASCO and our ALKtALK co-host Summer Farmen.

Living as well as possible is vital to our ALK community. Tune in at 6pm ET/11pm UK.

📺alkpositive.org/alktalk #LCSM #QualityofLife

We are becoming a FORCE! Read the full blog post at YLCI substack here: open.substack.com/pub/younglungc…

Thank you to ACS Journal Cancer for highlighting the #FlorezLab's Pregnancy and Lung Cancer Registry by Narjust Florez, MD, FASCO et al. on the front page of the June 1 issue‼️ 👏👏👏👏👏

Read June Issue now⤵️: acsjournals.onlinelibrary.wiley.com/toc/10970142/2…

The Case Against Antibody Drug Conjugates for Patients With Lung Cancers

hmpgloballearningnetwork.com/site/onc/confe…

Fantastic news for our ALK+ #lungcancer community 🙌

The U.S. FDA has granted breakthrough therapy designation to Nuvalent's NVL-655 for the treatment of patients with locally advanced or metastatic ALK+ LC who have been previously treated 2+ TKIs.

#LCSM #ResearchSavesLives

Amongst the enthusiasm for Tarlatamab approval, let’s please pause to remember the pts with SCLC who were the true pioneers. Their time, devotion, + belief in the hope of research made this advance possible 🙏 LiveLung LUNGevity Foundation GO2 for Lung Cancer IASLC #LCSM Jill Feldman

Looking for get involved in #Cancersupport advocacy? We're speaking about lung cancer but convo applicable to all. Join us for this live and lively discussion of advocacy across continents. IASLC ASCO, thnx Yvonne Diaz for hosting.

I've been thinking a lot about this. We are trapped in an old paradigm.

Research is making the crossover from site to molecular. Now funding treatment needs to make the shift.

Scientists were easy. Politicians will be much harder.

🚨Stay tuned for the next ALKtALK session by ALK Positive. This conversation will be centered around Empowering Wellness- Navigating body image, family dynamics, sexuality & #QOL with Narjust Florez, MD, FASCO‼️

🗓️: Sunday, May 19th 2024

⌚️: 6pm ET

alkpositive.org/alktalk

In this age of #PrecisionMedicine , shouldn't drugs be funded according to #biomarker vs tumour origin?

Elaine Lynch's #lungcancer is HER2+, associated w #breastcancer . Her family is self-funding Enhertu bc not indicated for lung & can't keep up
👉metro.co.uk/2024/05/13/nev… #lcsm